Burkholderia cepacia: Medical, taxonomic and ecological issues

Journal of Medical Microbiology

Volumn 45, Issue 6, 1996, Pages 395-407

  Govan, J R W ^a   Hughes, Jayne E ^a   Vandamme, P ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PEST CONTROL; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; ECOLOGY; HUMAN; IMMUNE DEFICIENCY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS; REVIEW; TAXONOMY;

EID: 0029972198     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-45-6-395     Document Type: Review

References (129)

1. Beckman W, Lessie TG. Response of Pseudomonas cepacia to β-lactam antibiotics: utilization of penicillin G as the carbon source. J Bacteriol 1979; 140: 1126-1128.
2. Burkholder WH. Sour skin, a bacterial rot of onion bulbs. Phytopath 1950; 40: 115-117.
3. Yabuuchi E, Kosako Y, Oyaizu H et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group H to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992; 36: 1251-1275.
4. Urakami T, Ito-Yoshida C, Araki H, Kijima T, Suzuki K-I, Komagata K. Transfer of Pseudomonas plantarii and Pseudomonas glumae to Burkholderia as Burkholderia spp. and description of Burkholderia vandii sp. nov. Int J Syst Bacteriol 1994; 44: 235-245.
5. Zhao NX, Qu CF, Wang ET, Chen WX. Phylogenetic evidence for the transfer of Pseudomonas cocovenenans (vanDamme et al 1960) to the genus Burkholderia as Burkholderia cocovenenans (vanDamme et al 1960) comb. nov. Int J Syst Bacteriol 1995; 45: 600-603.
6. 2-fixing isolates from rice in Vietnam. Int J Syst Bacteriol 1995; 45: 274-289.
7. Palleroni NJ. Genus I. Pseudomonas. In: Krieg NR, Holt JG (eds) Bergey's Manual of systemic bacteriology, vol 1. Baltimore, Williams and Wilkins Co. 1984: 141-159.
8. Wise MG, Shimkets LJ, McArthur JV. Genetic structure of a lotie population of Burkholderia (Pseudmonas) cepacia. Appl Environ Microbiol 1995; 61: 1791-1798.
9. Cheng H-P, Lessie TG. Multiple replicons constituting the genome of Pseudomonas cepacia 17616. J Bacteriol 1994; 176: 4034-4042.
10. Rodley PD, Römling U, Tümmler B. A physical genome map of the Burkholderia cepacia type strain. Mol Microbiol 1995; 17: 57-67.
11. Holmes B. The identification of Pseudomonas cepacia and its occurrence in clinical material. J Appl Bacteriol 1986; 61: 299-314.
12. Pitchford KC, Corey M, Highsmith AK et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr 1987; 111: 212-216.
13. Fisher MC, LiPuma JJ, Dasen SE et al. Source of Pseudomonas cepacia: ribotyping of isolates from patients and from the environment. J Pediatr 1993; 123: 745-747.
14. Butler SL, Doherty CJ, Hughes JE, Nelson JW, Govan JRW. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol 1995; 33: 1001-1004.
15. Mortensen JE, Fisher MC, LiPuma JJ. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment. Infect Control Hosp Epidemiol 1995; 16: 30-32.
16. Holmes A, Nolan R, Taylor R et al. An epidemic of Burkholderia (Pseudomonas) cepacia affecting patients with cystic fibrosis and without cystic fibrosis. Lancet (in press).
17. Govan JRW, Harris G. Typing of Pseudomonas cepacia by bacteriocin susceptibility and production. J Clin Microbiol 1985; 22: 490-494.
18. McLoughlin TJ, Quinn JP, Bettermann A, Bookland R. Pseudomonas cepacia suppression of sunflower wilt fungus and role of antifungal compounds in controlling the disease. Appl Environ Microbiol 1992; 58: 1760-1763.
19. Jayaswal RK, Fernandez M, Upadhyay RS et al. Antagonism of Pseudomonas cepacia against phytopathogenic fungi. Curr Microbiol 1993; 26: 17-22.
20. Abe M, Nakazawa T. Characterization of hemolytic and antifungal substance, cepalycin. from Pseudomonas cepacia. Microbiol Immunol 1994; 38: 1-9.
21. Aoki M, Uehara K, Tsuji K, Ono K, Iijima M. Large-scale culture and preservation methods of Pseudomonas cepacia B5 for biological control against bacterial wilt disease. Bioscience Biotech Biochem 1993; 57: 668-669.
22. Folsom BR, Chapman PJ, Pritchard PH. Phenol and trichloroethylene degradation by Pseudomonas cepacia G4: kinetics and interactions between substrates. Appl Environ Microbiol 1990; 56: 1279-1285.
23. Kilbane JJ, Chatterjee DK, Karns JS, Kellogg ST, Chakrabarty AM. Biodegradation of 2,4,5-trichlorophenoxyacetic acid by pure culture of Pseudomonas cepacia. Appl Environ Microbiol 1982; 44: 72-78.
24. Bevivino A, Tabacchioni S, Chiarni L, Carusi MV, del Gallo M, Visca P. Phenotypic comparison between rhizosphere and clinical isolates of Burkholderia cepacia. Microbiology 1994; 140: 1069-1077.
25. Johnson WM, Tyler SD, Rozee KR. Linkage analysis of geographical and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol 1994; 32: 924-930.
26. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (in press).
27. Dailey RH, Benner EJ. Necrotizing pneumonitis due to the pseudomonad "eugonic oxidizer-group 1". N Engl J Med 1968; 279: 361-362.
28. Basset DCJ, Stokes KJ, Thomas WRG. Wound infection with Pseudomonas multivorans: a water-borne contaminant of disinfectant solutions. Lancet 1970; 1: 1188-1191.
29. Phillips I, Eykyn S, Curtis MA, Snell JJS. Pseudomonas cepacia (multivorans) septicaemia in an intensive-care unit. Lancet 1971; 1: 375-377.
30. Cabrera HA, Drake MA. An epidemic in a coronary care unit caused by Pseudomonas species. Am J Clin Pathol 1975; 64: 700-704.
31. Poe RH, Marcus HR, Emerson GL. Lung abscess due to Pseudomonas cepacia. Am Rev Respir Dis 1977; 115: 861-865.
32. Goldman DA, Klinger JD. Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr 1986; 108: 806-812.
33. Jarvis WR, Olson D, Tablan O, Martone WJ. The epidemiology of nosocomial Pseudomonas cepacia infections: endemic infections. Eur J Epidemiol 1987; 3: 233-236.
34. Martone WJ, Tablan OC, Jarvis WR. The epidemiology of nosocomial epidemic Pseudomonas cepacia infections. Eur J Epidemiol 1987; 3: 222-232.
35. O'Neil KM, Herman JH, Modlin JF, Moxon ER, Winkelstein JA. Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. J Pediatr 1986; 108: 940-942.
36. Lacy DE, Spencer DA, Goldstein A, Weller PH, Darbyshire P. Chronic granulomatous disease presenting in childhood with Pseudomonas cepacia septicaemia. J Infect 1993; 27: 301-304.
37. Isles A, Maclusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-210.
38. Thomassen MJ, Demko CA, Klinger JD, Stern RC. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis 1985; 131: 791-796.
39. Anonymous. (Editorial). Pseudomonas cepacia - more than a harmless commensal? Lancet 1992; 339: 1385-1386.
40. Wong SN, Tam AY, Yung RW, Kwan EY, Tsoi NN. Pseudomonas septicemia in apparently healthy children. Acta Puediatr Scand 1991; 80: 515-520.
41. Pujol M, Corbella X, Carratala J, Gudiol F. Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. Clin Infect Dis 1992; 15: 887-888.
42. Hobson R, Gould I, Govan J. Burkholderia (Pseudomonas) cepacia as a cause of brain abscesses secondary to chronic suppurative otitis media. Eur J Clin Microbiol Infect Dis 1995; 14: 908-911.
43. LiPuma JJ, Fisher MC, Dasen SE, Mortensen JE, Stull TL. Ribotype stability of serial pulmonary isolates of Pseudomonas cepacia. J Infect Dis 1991; 164: 133-136.
44. Simpson IN, Finlay J, Winstanley DJ et al. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J Antimicrob Chemother 1994; 34: 353-361.
45. Yohalem DS, Lorbeer JW. Multilocus isoenzyme diversity among strains of Pseudomonas cepacia isolated from decayed onions, soils, and clinical sources. Syst Appl Microbiol 1994; 17: 116-124.
46. Pitt TL, Kaufmann ME, Patel PS, Benge LCA, Gaskin S, Livermore DM. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996; 44: 203-210.
47. Scordilis GE, Ree H, Lessie TG. Identification of transposable elements which activate gene expression in Pseudomonas cepacia. J Bacteriol 1987; 169: 8-13.
48. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4: 35-51.
49. Govan JRW, Nelson JW. Microbiology of cystic fibrosis lung infections: themes and issues. J R Soc Med 1993: 86 Suppl 20: 11-18.
50. Govan JRW, Glass S. The microbiology and therapy of cystic fibrosis lung infections. Rev Med Microbiol 1990; 1: 19-28.
51. Simmonds EJ, Conway SP, Ghoneim ATM, Ross H, Littlewood JM. Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child 1990; 65: 874-877.
52. Gladman G, Connor PJ, Williams RF, David TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child 1992; 67: 192-195.
53. Sajjan US, Corey M, Karmali MA. Forstner JF Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest 1992; 89: 648-656.
54. Lewin C, Doherty C, Govan JRW. In vitro activities of meropenem. PD 127391. PD 131628, ceftazidime. chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993; 37: 123-125.
55. Tablan OC, Carson LA, Cusick LB, Bland LA, Martone WJ, Jarvis WR. Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from simulated sputum specimens of patients with cystic fibrosis. J Clin Microbiol 1987; 25: 485-487.
56. Pitt TL, Govan JRW. Pseudomonas cepacia and cystic fibrosis. PHLS Microbiol Dig 1993; 10: 69-72.
57. Thomassen MJ, Demko CA, Doershuk CF, Stern RC, Klinger JD. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis 1986; 134: 669-671.
58. LiPuma JJ, Mortensen JE, Dasen SE et al. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr 1988; 113: 859-862.
59. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990; 336: 1094-1096.
60. Anderson DJ, Kuhns JS, Vasil ML, Gerding DN, Janoff EN. DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepacia from a nosocomial outbreak. J Clin Microbiol 1991; 29: 648-649.
61. Millar-Jones L, Paull A, Saunders Z, Goodchild MC. Transmission of Pseudomonas cepacia among cystic fibrosis patients. Lancet 1992; 340: 491.
62. Govan JRW, Brown PH, Maddison J et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
63. Smith DL, Gumery LB, Smith EG, Stableforth DE, Kaufmann ME, Pitt TL. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol 1993; 31: 3017-3022.
64. Bingen E, Botzenhart K, Chabanon G et al. Epidemiology of pulmonary infections by Pseudomonas in patients with cystic fibrosis: a consensus report. French Cystic Fibrosis Association (AFLM), Paris, 1993.
65. Corkill JE, Sisson PR, Smyth A et al. Application of pyrolysis mass spectroscopy and SDS-PAGE in the study of the epidemiology of Pseudomonas cepacia in cystic fibrosis. J Med Microbiol 1994; 41: 106-111.
66. Pegues DA, Carson LA, Tablan OC et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr 1994; 124: 694-702.
67. LiPuma JJ, Marks-Austin KA, Holsclaw DS, Winnie GB, Gilligan PH, Stull TL. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J 1994; 13: 716-719.
68. Ryley HC, Millar-Jones L, Paull A, Weeks J. Characterisation of Burkholderia cepacia from cystic fibrosis patients living in Wales by PCR ribotyping. J Med Microbiol 1995; 43: 436-441.
69. Sun L, Jiang R-Z, Steinbach S et al. The emergence of a highly transmissible lineage of cbl: Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nature Med 1995; 1: 661-666.
70. Revets H, Lauwers S. Molecular epidemiology of Burkholderia (Pseudomonas) cepacia. 20th European Cystic Fibrosis Conference. Brussels 1995: L21.
71. Whiteford ML, Wilkinson JD, McColl JH et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995; 50: 1194-1198.
72. Glass S, Govan JRW. Pseudomonas cepacia fatal pulmonary infection in a patient with cystic fibrosis. J Infect 1986; 13: 157-158.
73. Hardy KA, McGowan KL, Fisher MC, Schidlow DV. Pseudomonas cepacia in the hospital setting; lack of transmission between cystic fibrosis patients. J Pediatr 1986; 109: 51-54.
74. Taylor CJ, Howden R, Smith T, Spencer RC. Pseudomonas cepacia. Arch Dis Child 1994; 70: 358.
75. Steinbach S, Sun L, Jiang R-Z et al. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med 1994; 331: 981-987.
76. Cystic Fibrosis statement on Pseudomonas cepacia. Newsletter of the Association of Cystic Fibrosis Adults (UK). 1993; 37: 2-5.
77. Muhdi K, Edenborough FP, Gumery L et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax 1996; 51: 374-377.
78. Tablan OC, Chorba TL, Schidlow DV et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and cłinical outcome. J Pediatr 1985; 107: 382-387.
79. Lewin LO, Byard PJ, Davis PB. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990; 43: 125-131.
80. Brown P, Butler S, Nelson J, Doherty C, Govan J, Greening A. Pseudomonas cepacia (PC) in adult cystic fibrosis (CF): accelerated decline in lung function and increased mortality. Thorax 1993; 48: 425-426.
81. Taylor RFH, Gaya H, Hodson ME. Pseudomonas cepacia. pulmonary infection in patients with cystic fibrosis. Respir Med 1993; 87: 187-192.
82. Davidson DJ, Dorin JR, McLachlan G et al. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nature Genetic 1995; 9: 351-357.
83. Nelson JW, Butler SL, Krieg D, Govan JRW. Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol 1994; 8: 89-97.
84. Wilkinson SG, Pitt TL. Burkholderia (Pseudomonas) cepaaia: pathogenicity and resistance. Rev Med Microbiol 1995; 6: 10-17.
85. Speert DP, Bond M, Woodman RC, Curnutte JT. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J Infcet Dis 1994; 170: 1524-1531.
86. Butler SL, Nelson JW, Poxton IR, Govan JRW. Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. FEMS Immunol Med Microbiol 1994; 8: 285-292.
87. Nelson JW, Butler SL, Brown PH, Greening AP, Govan JRW. Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. J Med Microbiol 1993; 39: 39-47.
88. Pruksachartvuthi S, Aswapokee N, Thankerngpol K. Survival of Pseudomonas pseudomallei in human phagocytes. J Med Microbiol 1990; 31: 109-114.
89. Burns JL. Characterization of invasion of epithelial cells by Pseudomonas cepacia. Pediatr Pulmonol 1992; Suppl 8: abstract 201.
90. Tipper JL, Ingham E, Cove JH, Todd NJ, Littlewood JM, Kerr KG. An immunofluorescent assay for determining the invasiveness of A549 cells by Burkholderia (Pseudomonas) cepacia. 20th European Cystic Fibrosis Conference. Brussels 1995: P15.
91. Miller VL. Tissue-culture invasion: fact or artefact. Trends Microbiol 1995; 3: 69-71.
92. Pier GB, Grout M, Zaidi TS et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271: 64-67.
93. Landers PD, Tipper JL, Rowbotham TJ, Kerr KG. Survival and multiplication of Burkholderia (Pseudomonas) cepacia within the free-living amoeba Acanthamoeeba polyphaga. 20th European Cystic Fibrosis Conference. Brussels 1995: P4.
94. Aronoff SC, Quinn FJ, Stern RC. Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatr Pulmonol 1991; 11: 289-293.
95. Aronoff SC, Stern RC. Serum IgG antibody to outer membrane antigens of Pseudomonas cepacia and Pseudomonas aeruginosa in cystic fibrosis. J Infcet Dis 1988; 157: 934-940.
96. Lacy DE, Smith AW, Stableforth DE, Smith G, Weller PH, Brown MRW. Serum IgG response to Burkholderia cepacia outer membrane antigens in cystic fibrosis: assessment of cross-reactivity with Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 1995; 10: 253-262.
97. Burnie JP, Al-Wardi EJ, Williamson P, Matthews RC, Webb K, David T. Defining potential targets for immunotherapy in Burkholderia cepacia infection. FEMS Immunol Med Microbiol 1995; 10: 157-164.
98. Parr TR, Moore RA, Moore LV, Hancock REW. Role of porins in intrinsic antibiotic resistance of Pseudomonas cepacia. Antimicrob Agents Chemother 1987; 31: 121-123.
99. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.
100. Döring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: S114-S117.
101. Suter S. The role of bacterial proteases in the pathogenesis of cystic fibrosis. Am J Respir Crit Care Med 1994; 150: S118-S122.
102. Elborn JS, Dodd M, Maddison J et al. Clinical and inflammatory responses in CF patients infected with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr Pulmonol 1994; 10 Suppl: 287.
103. Shaw D. The regulation and biological activity of cell surface determinants in model opportunist aerobic and anaerobic bacterial pathogens. PhD thesis. University of Edinburgh: 1995.
104. Shaw D, Poxton IR, Govan JRW. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. FEMS Immunol Med Microbiol 1995; 11: 99-106.
105. Shaw D, Poxton IR, Govan JRW. The induction of TNF by B. cepacia and P. aeruginosa lipopolysaccharide. 20th European Cystic Fibrosis Conference, Brussels 1995: O9.
106. Kiska DL, Kerr A, Jones MC et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other Gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 1996; 34: 886-891.
107. Leff LG, Kernan RM, McArthur JV, Shimkets LJ. Identification of aquatic Burkholderia (Pseudomonas) cepacia by hybridization with species-specific rRNA gene probes. Appl Environ Microbiol 1995; 61: 1634-1636.
108. Vandamme P. Emerging new "Pseudomonas" species in cystic fibrosis. 20th European Cystic Fibrosis Conference, Brussels 1995: L1.
109. Ursing JB, Rosello-Mora RA, Garcia-Valdes E, Lalucat J. A pragmatic approach to the nomenclature of phenotypically similar genomic groups. Int J Syst Bacteriol 1995; 45: 604.
110. Stableforth DE, Smith DL. Pseudomonas cepacia in cystic fibrosis. Thorax 1994; 49: 629-630.
111. Govan JRW. Burkholderia cepacia in cystic fibrosis. N Engl J Med 1995; 332: 819-820.
112. LiPuma JJ, Stull TL. Burkholderia cepacia in cystic fibrosis. N Engl J Med 1995; 332: 820.
113. Butler SL, Nelson JW, Govan JRW. Cell surface characteristics of Pseudomonas cepacia isolates from patients with cystic fibrosis. X1 International CF Congress, Dublin 1992. Abstract TP8.
114. Sajjan US, Forstner JF. Identification of the mucin-binding adhesin of Pseudomonas cepacia isolated from patients with cystic fibrosis. Inject Immun 1992; 60: 1434-1440.
115. Sajjan US, Sun L, Goldstein R, Forstner JF. Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the chlA major subunit pilin gene and novel morphology of the assembled appendage fibers. J Bacteriol 1995; 177: 1030-1038.
116. Sylvester FA, Sajjan US, Forstner JF. Burkholderia (basonym Pseudomonas) cepacia binding to lipid receptors. Infect Immun 1996; 64: 1420-1425.
117. Nelson JW, Doherty CJ, Brown PH, Greening AP, Kaufmann ME, Govan JRW. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet 1991; 338: 1525.
118. Burdge DR, Nakiclna EM, Noble MA. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Infect Control Hosp Epidemiol 1993; 14: 127-130.
119. Hutchinson GR, Parker S, Pryor JA et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant. Gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996; 34: 584-587.
120. Takigawa K, Fujita J, Negayama K et al. Nosocomial outbreak of Pseudomonas cepacia respiratory infection in immunocompromised patients associated with contaminated nebulizer devices. Kansenshogaku Zasshi 1993; 67: 1115-1125.
121. Humphreys H, Peckham D, Patel P, Knox A. Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis. Thorax 1994; 49: 1157-1159.
122. Homma Y, Sato Z, Hirayama F, Kanno K, Shirahama H, Suzui T. Production of antibiotics by Pseudomonas cepacia as an agent for biological control of soilborn plant pathogens. Soil Biol Biochem 1989; 21: 723-728.
123. Fridlander M, Inbar J, Chet I. Biological control of soilborne plant pathogens by a β-1,3-glucanase-producing Pseudomonas cepacia. Soil Biol Biochem 1993; 25: 1211-1222.
124. Bhat MA, Tsuda M, Horike K, Nozaki M, Vaidyanathan CS, Nakazawa T. Identification and characterization of a new plasmid carrying genes for degradation of 2,4-dichlorophenoxyacetate from Pseudomonas cepacia CSV90. Appl Environ Microbiol 1994; 60: 307-312.
125. Havel J, Reineke W. Degradation of Aroclor 1221 in soil by a hybrid pseudomonad. FEMS Microbiol Lett 1993; 108: 211-217.
126. Krumme ML, Timmis KN, Dwyer DF. Degradation of trichloroethylene by Pseudomonas cepacia G4 and the constitutive mutant strain G4 5223 PR1 in aquifer microcosms. Appl Environ Microbiol 1993; 59: 2746-2749.
127. Anonymous. Less beef, more brains. Lancet 1996; 347: 915.
128. Taplin D, Bassett DCJ, Mertz PM. Foot lesions associated with Pseudomonas cepacia. Lancet 1971; 2: 568-571.
129. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-236.